Merck Weighs on Dow After Clinical Trial Miss

Investing.com – Drugmaker Merck was a drag on the Jones in midday trading Tuesday as the blue-chip index struggled to follow the S&P and Nasdaq into positive territory.

Merck (NYSE:) shares dropped 2,2% following a disappointing clinical trial for its market-leading lung cancer treatment.

The company said after the bell Monday that its drug Keytruda did not meet a statistically significant goal in treating non-small cell lung cancer in combination with chemotherapy in a phase 3 trial.

Merck’s loss of a little more than $2 accounted for more than 13 points of the Dow’s 31-point loss.

Keytruda has been approved to treat non-small cell lung cancer, which accounts for around 85% of lung cancer cases, and currently holds a dominant position in that market.

Small-cell lung cancer accounts for about 10% to 15% of all cases of lung cancer, Merck said. It said the five-year survival rate for patients diagnosed in the U.S. with any stage of SCLC is estimated to be 6%.

— Reuters contributed to this report.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.